VEGFA and brain neoplasm: Anti-angiogenic therapies targeting vascular-endothelial growth factor (VEGF) and cognate receptors provided clinical benefits in different kind of solid tumours (including colorectal, kidney, lung, ovarian, brain tumours) [129], although often, response to therapy was limited in time and in a fraction of treated patients.